ProfileGDS4814 / ILMN_1692651
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 94% 94% 95% 94% 94% 95% 94% 94% 94% 94% 94% 94% 94% 94% 94% 94% 95% 94% 94% 95% 94% 95% 95% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)741.44194
GSM780708Untreated after 4 days (C2_1)793.71194
GSM780709Untreated after 4 days (C3_1)873.74695
GSM780719Untreated after 4 days (C1_2)785.30794
GSM780720Untreated after 4 days (C2_2)803.59694
GSM780721Untreated after 4 days (C3_2)909.85495
GSM780710Trastuzumab treated after 4 days (T1_1)791.42694
GSM780711Trastuzumab treated after 4 days (T2_1)799.20194
GSM780712Trastuzumab treated after 4 days (T3_1)695.63994
GSM780722Trastuzumab treated after 4 days (T1_2)785.83994
GSM780723Trastuzumab treated after 4 days (T2_2)791.69394
GSM780724Trastuzumab treated after 4 days (T3_2)744.28394
GSM780713Pertuzumab treated after 4 days (P1_1)713.57594
GSM780714Pertuzumab treated after 4 days (P2_1)803.59694
GSM780715Pertuzumab treated after 4 days (P3_1)793.50494
GSM780725Pertuzumab treated after 4 days (P1_2)787.63194
GSM780726Pertuzumab treated after 4 days (P2_2)809.51195
GSM780727Pertuzumab treated after 4 days (P3_2)732.02794
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)794.92994
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)817.94795
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)786.09494
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)817.94795
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)808.84295